Changes at the top at Silence Therapeutics

25 May 2016

UK biotech Silence Therapeutics (AIM: SLN) has announced a number of changes to its management as it positions itself as a leading RNA technology company.

The UK-based company, which focuses on the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, has made changes to its board, set up a technology advisory board, and made a senior scientific appointment.

David Ellam is to become Silence’s chief financial officer and a director from July 18. His previous senior finance roles have been with companies in the USA and the UK, most recently with US biotech BioMarin Pharmaceutical (Nasdaq: BMRN).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK